ImmunoPEGliposome-mediated reduction of blood and brain amyloid levels in a mouse model of Alzheimer's disease is restricted to aged animals

Ordóñez-Gutiérrez, Lara; Posado-Fernández, Adrián; Ahmadvand, Davoud; Lettiero, Barbara; Wu, Lin; Antón, Marta; Flores, Orfeu; Moghimi, S. Moein

doi:10.1016/j.biomaterials.2016.07.027

Cited by 33 publications

(29 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…27,28 So far, only three nanoparticulate systems with enhanced affinity for Aβ have been designed to counterbalance the deficient Aβ clearance mechanism in vivo: (i) PEGylated liposomes bifunctionalized with a peptide deriving from the Apo E receptor-binding domain for blood-brain barrier (BBB) targeting and phosphatidic acid for Aβ binding, 29,30 (ii) Apo E3-reconstituted high density lipoprotein (Apo E3-rHDL) 31 and (iii) liposomes surface-functionalized by a monoclonal anti-A antibody. 32 This latter study is very interesting owing to the high affinity and specificity of antibodies towards their targets (antigens), reducing off-site binding and preventing substantial decrease of the therapeutic efficiency. 33 However, a proof of efficacy;…”

Section: Introductionmentioning

confidence: 99%

Antibody-functionalized polymer nanoparticle leading to memory recovery in Alzheimer's disease-like transgenic mouse model

Carradori

Balducci

et al. 2018

Nanomedicine: Nanotechnology, Biology and Medicine

Self Cite

118

View full text Add to dashboard Cite

Alzheimer's disease (AD) is a neurodegenerative disorder related, in part, to the accumulation of amyloid-β peptide (Aβ) and especially the Aβ peptide 1-42 (Aβ). The aim of this study was to design nanocarriers able to: (i) interact with the Aβ in the blood and promote its elimination through the "sink effect" and (ii) correct the memory defect observed in AD-like transgenic mice. To do so, biodegradable, PEGylated nanoparticles were surface-functionalized with an antibody directed against Aβ. Treatment of AD-like transgenic mice with anti-Aβ-functionalized nanoparticles led to: (i) complete correction of the memory defect; (ii) significant reduction of the Aβ soluble peptide and its oligomer level in the brain and (iii) significant increase of the Aβ levels in plasma. This study represents the first example of Aβ monoclonal antibody-decorated nanoparticle-based therapy against AD leading to complete correction of the memory defect in an experimental model of AD.

show abstract

Section: Introductionmentioning

confidence: 99%

Antibody-functionalized polymer nanoparticle leading to memory recovery in Alzheimer's disease-like transgenic mouse model

Carradori

Balducci

et al. 2018

Nanomedicine: Nanotechnology, Biology and Medicine

Self Cite

118

View full text Add to dashboard Cite

show abstract

“…In this technique the same antibody is used with a specific sequence for uptake and detection [ 65 ]. Another new technique is the use of antibodies using STAB-MAb bound to PEGylated liposomes [ 32 ]. Some new protocols for o-ELISA have been developed for soluble oligomers for β-amyloid protein in the human brain.…”

Section: Resultsmentioning

confidence: 99%

“…Other theories state that such diseases may be due to a mutation [ 28 ], increased stress in the amyloid precursor protein (APP)/Aβ metallic transport system, lifestyle [ 29 ], and promotion of ROS [ 30 ]. Another important factor is poor processing of the APP [ 31 ] influenced by β-proteins (BACE1) and γ-secretases [ 32 ], which promote protein aggregation. This information reveals the importance of amyloid deposition’s importance in global health [ 1 , 2 , 23 ].…”

Section: Introductionmentioning

confidence: 99%

Amyloid Biomarkers in Conformational Diseases at Face Value: A Systematic Review

Avila-Vazquez

Altamirano-Bustamante

2017

Molecules

View full text Add to dashboard Cite

Conformational diseases represent a new aspect of proteomic medicine where diagnostic and therapeutic paradigms are evolving. In this context, the early biomarkers for target cell failure (neurons, β-cells, etc.) represent a challenge to translational medicine and play a multidimensional role as biomarkers and potential therapeutic targets. This systematic review, which follows the PICO and Prisma methods, analyses this new-fangled multidimensionality, its strengths and limitations, and presents the future possibilities it opens up. The nuclear diagnosis methods are immunoassays: ELISA, immunodot, western blot, etc., while the therapeutic approach is focused on pharmaco- and molecular chaperones.

show abstract

“…The chronic neurodegenerative disease, Alzheimer’s disease, is caused by the accumulation of neurofibrillary tangles and amyloid plaques (Aβ), two core pathological hallmarks, in the brain. Ordóñez-Gutiérrez et al, functionalized the surface of PEGylated liposomes by using a monoclonal anti-Aβ antibody to capture Aβ in the periphery and showed that these immunoliposomes had a higher therapeutic efficacy than the free monoclonal antibody [ 65 ].…”

Section: Liposomes As Drug Delivery Vesiclesmentioning

confidence: 99%

Engineering Smart Targeting Nanovesicles and Their Combination with Hydrogels for Controlled Drug Delivery

et al. 2020

View full text Add to dashboard Cite

Smart engineered and naturally derived nanovesicles, capable of targeting specific tissues and cells and delivering bioactive molecules and drugs into them, are becoming important drug delivery systems. Liposomes stand out among different types of self-assembled nanovesicles, because of their amphiphilicity and non-toxic nature. By modifying their surfaces, liposomes can become stimulus-responsive, releasing their cargo on demand. Recently, the recognized role of exosomes in cell-cell communication and their ability to diffuse through tissues to find target cells have led to an increase in their usage as smart delivery systems. Moreover, engineering “smarter” delivery systems can be done by creating hybrid exosome-liposome nanocarriers via membrane fusion. These systems can be loaded in naturally derived hydrogels to achieve sustained and controlled drug delivery. Here, the focus is on evaluating the smart behavior of liposomes and exosomes, the fabrication of hybrid exosome-liposome nanovesicles, and the controlled delivery and routes of administration of a hydrogel matrix for drug delivery systems.

show abstract

ImmunoPEGliposome-mediated reduction of blood and brain amyloid levels in a mouse model of Alzheimer's disease is restricted to aged animals

Cited by 33 publications

References 55 publications

Antibody-functionalized polymer nanoparticle leading to memory recovery in Alzheimer's disease-like transgenic mouse model

Antibody-functionalized polymer nanoparticle leading to memory recovery in Alzheimer's disease-like transgenic mouse model

Amyloid Biomarkers in Conformational Diseases at Face Value: A Systematic Review

Engineering Smart Targeting Nanovesicles and Their Combination with Hydrogels for Controlled Drug Delivery

Contact Info

Product

Resources

About